Sales Effectiveness

How the Metsera deal extends Pfizer’s 25-year blueprint for growth.

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

From CRM saturation to commercial orchestration.

The model imagines a new future in which traditional pharmacy distribution and access channels are bypassed.

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Pharmaceutical companies embrace direct-to-consumer sales and price cuts amid tariff changes and Trump's push for lower drug costs in the US.

At the heart of this moment is a growing unpredictability in how U.S. healthcare policy is being shaped.

With ever-increasing costs to put a single molecule on the market, the pressure to reach clinical milestones quickly and efficiently often drives a focus on short-term gains that can create significant long-term liabilities, jeopardizing the path to commercial viability.

Kitamura discusses implementing cost management initiatives and positioning the company to weather near-term challenges.

Ryan Quigley, CEO of Inizio, details the current usage of AI and other advanced technologies.

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, details how products having an insufficient relative advantage, enter the market too late, or are incompatible with perceived needs can cause problems at launch.

The key steps for pharma in pivoting from proof-of-concept experimenting to enterprise-scale value.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Executives are exploring various strategies to prepare for an uncertain pricing environment in the coming months and years.

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, discusses the current state of the pharma industry and the factors that are impacting its growth potential.

Marc Stapley, CEO of Veracyte, explains how investors are reacting to recent advancements in cancer care.

As the GLP market begins to settle, pharma companies and investors are looking to predict what comes next.

With insured patients less likely to benefit, who actually does benefit from D2C?

Derrick Gastineau discusses how the focus on weight loss medications has shifted in recent years.

Michael Grosberg discusses how people with insurance will be impacted by D2C drug sales.